PP
PRLD icon

PDT Partners’s Prelude Therapeutics PRLD Stock Holding History

PDT Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,641
Closed -$84K – 839
2022
Q3 		$84K Sell
12,641
-31,090
-71% -$210K 0.01% 790
2022
Q2 		$228K Sell
43,731
-28,091
-39% -$143K 0.02% 801
2022
Q1 		$496K Buy
71,822
+35,915
+100% +$328K 0.04% 583
2021
Q4 		$447K Buy
+35,907
New +$584K 0.03% 559

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PDT Partners's PRLD Position: Q4 2022 in Review

PDT Partners sold out of Prelude Therapeutics (PRLD) in Q4 2022, closing a stake of 12,641 shares — an estimated $84K sold.

PDT Partners first reported a position in PRLD in Q4 2021 and held it in 4 quarters. The position peaked at $496K in Q1 2022. 60 funds tracked by Wall St. Rank hold PRLD as of Q4 2022.

  • PDT Partners reported no remaining Prelude Therapeutics position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 12,641 Prelude Therapeutics shares in Q4 2022, an estimated $84K.
  • PDT Partners first reported a position in Prelude Therapeutics in Q4 2021 and held it in 4 quarters.
  • PDT Partners's Prelude Therapeutics position peaked at $496K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.